Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Kindred Biosciences, Inc.    KIN

KINDRED BIOSCIENCES, INC.

(KIN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Kindred Biosciences : to Announce Third Quarter 2020 Financial Results

10/29/2020 | 08:50am EST

San Francisco - Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its third quarter 2020 financial results on November 9, 2020, after the market close.

The Company will host a conference call at 4:30 p.m. Eastern time/1:30 p.m. Pacific time that day.

Access the call by dialing toll-free (855) 433-0927 from the U.S. or (484) 756-4262 internationally, and using conference ID 5758359.

The call will also be webcast live here, with a replay available at that link for 30 days.

About Kindred Biosciences

Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The company's strategy is to identify targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated targets for dogs and cats. KindredBio has a deep pipeline of novel biologics in development across many therapeutic classes, alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio.

Contact:

Katja Buhrer

Tel: (917) 969-3438

Email: katja.buhrer@kindredbio.com

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about KINDRED BIOSCIENCES, INC.
11/25KINDRED BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (for..
AQ
11/20KINDRED BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (for..
AQ
11/09KINDRED BIO : 3Q Earnings Snapshot
AQ
11/09KINDRED BIOSCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
11/09KINDRED BIOSCIENCES, INC. : Results of Operations and Financial Condition (form ..
AQ
10/29KINDRED BIOSCIENCES : to Announce Third Quarter 2020 Financial Results
AQ
10/08KINDRED BIOSCIENCES : Announces Expansion of Manufacturing Agreement with Vaxart..
AQ
10/07KINDRED BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (for..
AQ
09/17KINDRED BIOSCIENCES : Announces Positive Results from Pivotal Efficacy Study of ..
AQ
09/16KINDRED BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (for..
AQ
More news
Financials (USD)
Sales 2020 42,1 M - -
Net income 2020 -22,6 M - -
Net Debt 2020 - - -
P/E ratio 2020 -6,72x
Yield 2020 -
Capitalization 158 M 158 M -
Capi. / Sales 2020 3,75x
Capi. / Sales 2021 10,2x
Nbr of Employees 156
Free-Float 93,8%
Chart KINDRED BIOSCIENCES, INC.
Duration : Period :
Kindred Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KINDRED BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 11,42 $
Last Close Price 3,90 $
Spread / Highest target 259%
Spread / Average Target 193%
Spread / Lowest Target 131%
EPS Revisions
Managers
NameTitle
Richard H. Chin President, Chief Executive Officer & Director
Wendy Wee Secretary, Chief Financial & Accounting Officer
Hangjun Zhan Chief Scientific Officer
Kathy Vannatta Senior Director-Clinical Development, Quality
Ervin Veszprémi Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
KINDRED BIOSCIENCES, INC.-52.83%158
GILEAD SCIENCES, INC.-8.43%74 585
VERTEX PHARMACEUTICALS-0.39%56 714
REGENERON PHARMACEUTICALS35.38%53 649
WUXI APPTEC CO., LTD.56.53%37 992
BIONTECH SE209.80%25 273